These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 25159238)

  • 21. Two-year treatment with rosuvastatin reduces carotid intima-media thickness in HIV type 1-infected patients receiving highly active antiretroviral therapy with asymptomatic atherosclerosis and moderate cardiovascular risk.
    Calza L; Manfredi R; Colangeli V; Trapani FF; Salvadori C; Magistrelli E; Danese I; Verucchi G; Serra C; Viale P
    AIDS Res Hum Retroviruses; 2013 Mar; 29(3):547-56. PubMed ID: 23098891
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of central obesity, low high-density lipoprotein cholesterol and C-reactive protein polymorphisms on C-reactive protein levels during treatment with Rosuvastatin (10 mg Daily).
    Hu M; Lee MH; Mak VW; Tomlinson B
    Am J Cardiol; 2010 Dec; 106(11):1588-93. PubMed ID: 21094359
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of the effects of high doses of rosuvastatin versus atorvastatin on the subpopulations of high-density lipoproteins.
    Asztalos BF; Le Maulf F; Dallal GE; Stein E; Jones PH; Horvath KV; McTaggart F; Schaefer EJ
    Am J Cardiol; 2007 Mar; 99(5):681-5. PubMed ID: 17317371
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cholesterol level goal attainment with statins: clinical management guideline recommendations versus management in actual clinical practice.
    Heintjes EM; Penning-van Beest FJ; Plat AW; Meerding WJ; Webb K; Sturkenboom MC; Herings RM
    Pharmacotherapy; 2012 Jul; 32(7):631-41. PubMed ID: 22760692
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relation of baseline high-sensitivity C-reactive protein level to cardiovascular outcomes with rosuvastatin in the Justification for Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER).
    Ridker PM; MacFadyen J; Libby P; Glynn RJ
    Am J Cardiol; 2010 Jul; 106(2):204-9. PubMed ID: 20599004
    [TBL] [Abstract][Full Text] [Related]  

  • 26. LDL-C/HDL-C ratio in subjects with cardiovascular disease and a low HDL-C: results of the RADAR (Rosuvastatin and Atorvastatin in different Dosages And Reverse cholesterol transport) study.
    Jukema JW; Liem AH; Dunselman PH; van der Sloot JA; Lok DJ; Zwinderman AH
    Curr Med Res Opin; 2005 Nov; 21(11):1865-74. PubMed ID: 16307708
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dose-dependent effect of rosuvastatin treatment on HDL-subfraction phenotype in patients with primary hyperlipidemia.
    Kostapanos MS; Milionis HJ; Filippatos TD; Christogiannis LG; Bairaktari ET; Tselepis AD; Elisaf MS
    J Cardiovasc Pharmacol Ther; 2009 Mar; 14(1):5-13. PubMed ID: 19246334
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improvement in endothelium dysfunction in diabetics treated with statins: a randomized comparison of atorvastatin 20 mg versus rosuvastatin 10 mg.
    Brunetti ND; Maulucci G; Casavecchia GP; Distaso C; De Gennaro L; Pellegrino PL; Di Biase M
    J Interv Cardiol; 2007 Dec; 20(6):481-7. PubMed ID: 18042053
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
    Jones PH; Hunninghake DB; Ferdinand KC; Stein EA; Gold A; Caplan RJ; Blasetto JW;
    Clin Ther; 2004 Sep; 26(9):1388-99. PubMed ID: 15531001
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of rosuvastatin (5 mg and 10 mg) twice a week in patients intolerant to daily statins.
    Gadarla M; Kearns AK; Thompson PD
    Am J Cardiol; 2008 Jun; 101(12):1747-8. PubMed ID: 18549851
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increased morning blood pressure surge and coronary microvascular dysfunction in patient with early stage hypertension.
    Caliskan M; Caliskan Z; Gullu H; Keles N; Bulur S; Turan Y; Kostek O; Ciftci O; Guven A; Aung SM; Muderrisoglu H
    J Am Soc Hypertens; 2014 Sep; 8(9):652-9. PubMed ID: 25224866
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and efficacy of rosuvastatin therapy for the prevention of hyperlipidemia in adult cardiac transplant recipients.
    Samman A; Imai C; Straatman L; Frolich J; Humphries K; Ignaszewski A
    J Heart Lung Transplant; 2005 Aug; 24(8):1008-13. PubMed ID: 16102434
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness and tolerability of every-other-day rosuvastatin dosing in patients with prior statin intolerance.
    Backes JM; Venero CV; Gibson CA; Ruisinger JF; Howard PA; Thompson PD; Moriarty PM
    Ann Pharmacother; 2008 Mar; 42(3):341-6. PubMed ID: 18285559
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design of the rosuvastatin pretreatment to reduce embolization during Carotid Artery Stenting trial.
    De Carlo M; Cortese B; Pennesi M; Misuraca L; Conte L; Pitì A; Petronio AS; Balbarini A
    J Cardiovasc Med (Hagerstown); 2014 Jul; 15(7):595-600. PubMed ID: 24922046
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term efficacy and safety of rosuvastatin 40 mg in patients with severe hypercholesterolemia.
    Stein EA; Amerena J; Ballantyne CM; Brice E; Farnier M; Guthrie RM; Harats D; Ma PT; Le Maulf F; Melezínková H; Gold A; Sager P
    Am J Cardiol; 2007 Nov; 100(9):1387-96. PubMed ID: 17950795
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impaired coronary flow reserve is associated with increased echocardiographic epicardial fat thickness in metabolic syndrome patients.
    Tok D; Çağli K; Kadife I; Turak O; Özcan F; Başar FN; Gölbaşi Z; Aydoğdu S
    Coron Artery Dis; 2013 May; 24(3):191-5. PubMed ID: 23291861
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of rosuvastatin therapy on carotid plaque morphology and composition in moderately hypercholesterolemic patients: a high-resolution magnetic resonance imaging trial.
    Underhill HR; Yuan C; Zhao XQ; Kraiss LW; Parker DL; Saam T; Chu B; Takaya N; Liu F; Polissar NL; Neradilek B; Raichlen JS; Cain VA; Waterton JC; Hamar W; Hatsukami TS
    Am Heart J; 2008 Mar; 155(3):584.e1-8. PubMed ID: 18294500
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of coadministration of rosuvastatin, ezetimibe, and colestimide in heterozygous familial hypercholesterolemia.
    Kawashiri MA; Nohara A; Noguchi T; Tada H; Nakanishi C; Mori M; Konno T; Hayashi K; Fujino N; Inazu A; Kobayashi J; Mabuchi H; Yamagishi M
    Am J Cardiol; 2012 Feb; 109(3):364-9. PubMed ID: 22112743
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER).
    Ridker PM; MacFadyen JG; Fonseca FA; Genest J; Gotto AM; Kastelein JJ; Koenig W; Libby P; Lorenzatti AJ; Nordestgaard BG; Shepherd J; Willerson JT; Glynn RJ;
    Circ Cardiovasc Qual Outcomes; 2009 Nov; 2(6):616-23. PubMed ID: 20031900
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Relationship between regression of hypertensive left ventricular hypertrophy and improvement of coronary flow reserve].
    Xu R; Zhang Y; Zhang M; Ge ZM; Li XC; Zhang W
    Zhonghua Yi Xue Za Zhi; 2003 Apr; 83(8):658-61. PubMed ID: 12887823
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.